My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Bharti Infratel jumps on reports of brokerage upgrade
Mar 03,2017

Meanwhile, the S&P BSE Sensex was down 28.67 points or 0.1% at 28,811.12.

On the BSE, 6.03 lakh shares were traded on the counter so far as against the average daily volumes of 2.28 lakh shares in the past one quarter. The stock had hit a high of Rs 310 and a low of Rs 293 so far during the day.

The stock had hit a 52-week high of Rs 412.55 on 28 July 2016 and a 52-week low of Rs 283.10 on 28 February 2017. It had underperformed the market over the past one month till 2 March 2017, sliding 0.79% compared with the Sensexs 2.17% rise. The scrip had also underperformed the market over the past one quarter, declining 24.9% as against the Sensexs 9.95% rise.

The large-cap company has equity capital of Rs 1849.61 crore. Face value per share is Rs 10.

The foreign brokerage reportedly feels that with recent sharp correction in Bharti Infratel stock, risks related to tenancy impact due to likely Vodafone-Idea merger are overdone now. These merger & acquisition (M&A) deals in telecom space would be a positive catalyst for Bharti Infratels growth and strengthen its position in the tower space in India, as per the brokerages view.

Shares of Bharti Infratel declined 10.1% at its closing price of Rs 289.90 yesterday, 2 March 2017, from its closing of Rs 322.40 on 15 February 2017.

On a consolidated basis, Bharti Infratels net profit rose 25.3% to Rs 620.40 crore on 9.6% growth in net sales to Rs 1530 crore in Q3 December 2016 over Q3 December 2015.

Bharti Infratel is one of the leading providers of tower and related infrastructure. It deploys, owns and manages telecom towers and communication structures, for various mobile operators.

Powered by Capital Market - Live News

Nalco jumps 17.14% in six sessions
Mar 03,2017

The announcement was made after market hours yesterday, 2 March 2017.

The stock has jumped 17.14% to its current ruling price of Rs 75.85 in six sessions, from a close of Rs 64.75 on 22 February 2017.

Meanwhile, the S&P BSE Sensex was down 55.43 points or 0.19% at 28,784.36.

On the BSE, 4.73 lakh shares were traded in the counter so far as against average daily volume of 5.96 lakh shares in the past one quarter. The stock had hit a high of Rs 77.05 and a low of Rs 74.50 so far during the day. The stock had hit a 52-week high of Rs 79.35 on 27 January 2017. The stock had hit a 52-week low of Rs 32.95 on 2 March 2016.

It had underperformed the market over the past one month till 2 March 2017, gaining 2.03% compared with the Sensexs 2.17% rise. The scrip had, however, outperformed the market over the past one quarter, advancing 38.84% as against the Sensexs 9.95% rise.

The large-cap company has equity capital of Rs 966.46 crore. Face value per share is Rs 5.

Similarly, the hydrate production at its refinery has also registered an increase of 6.8%. The hydrate production till February 2017 was 18.9 lakh tonnes as against 17.7 lakh tonnes for the same period in the previous year. At its aluminium smelter, cast metal production grew by 3.79% and the aluminium metal sales grew by 2.68%.

Separately, the companys board of directors has approved payment of interim dividend of Rs 2.80 per share for the financial year ending 31 March 2017. The announcement was made after market hours yesterday, 2 March 2017.

Meanwhile, as per recent reports, China had ordered aluminium and steel producers in 28 cities to slash output during winter, as Beijing intensifies its war on smog.

Nalcos net profit fell 2.7% to Rs 143.92 crore on 13.9% rise in net sales Rs 1963.81 crore in Q3 December 2016 over Q3 December 2015.

State-run National Aluminium Company (Nalco) has integrated and diversified operations in mining, metal and power. The Government of India (GoI) held 74.58% stake in the company (as per the shareholding pattern as on 31 December 2016).

Powered by Capital Market - Live News

Apollo Hospitals Enterprise leads losers on BSEs A group
Mar 03,2017

Apollo Hospitals Enterprise shed 4.48% to Rs 1,257 on reports of stake sale by a Malaysian sovereign fund. The stock topped the losers in A group. On the BSE, 6.38 lakh shares were traded on the counter so far as against the average daily volumes of 12,000 shares in the past two weeks.

Media reports suggested that Khazanah Berhads subsidiary Integrated (Mauritius) Healthcare Holdings offloaded shares of Apollo Hospitals Enterprise through block deals on the stock exchanges today, 3 March 2017. Integrated (Mauritius) Healthcare Holdings owned 10.85% stake in Apollo Hospitals Enterprise end December 2016.

Jain Irrigation Systems fell 3.3% at Rs 89.30. The stock was the second biggest loser in A group. On the BSE, 3.4 lakh shares were traded on the counter so far as against the average daily volumes of 3.03 lakh shares in the past two weeks.

Amtek Auto fell 3.05% at Rs 36.50. The stock was the third biggest loser in A group. On the BSE, 2.4 lakh shares were traded on the counter so far as against the average daily volumes of 7.55 lakh shares in the past two weeks.

NCC declined 2.84% at Rs 78.70. The stock was the fourth biggest loser in A group. On the BSE, 2.4 lakh shares were traded on the counter so far as against the average daily volumes of 7.55 lakh shares in the past two weeks.

Bajaj Finserv dropped 2.7% at Rs 3,783.15. The stock was the fifth biggest loser in A group. On the BSE, 7,239 shares were traded on the counter so far as against the average daily volumes of 18,000 shares in the past two weeks.

Powered by Capital Market - Live News

Volumes jump at Geometric counter
Mar 03,2017

Geometric clocked volume of 10.15 lakh shares by 13:46 IST on BSE, a 132.51-times surge over two-week average daily volume of 8,000 shares. The stock was up 0.75% at Rs 262.75.

Apollo Hospitals Enterprise notched up volume of 6.37 lakh shares, a 52.55-fold surge over two-week average daily volume of 12,000 shares. The stock was down 4.51% at Rs 1,256.50.

Vista Pharmaceuticals saw volume of 25.74 lakh shares, a 24.34-fold surge over two-week average daily volume of 1.06 lakh shares. The stock surged by its upper circuit limit of 20% at Rs 30.90.

Dhampur Sugar Mills clocked volume of 3.34 lakh shares, a 5.52-fold surge over two-week average daily volume of 60,000 shares. The stock jumped 10.53% at Rs 205.75.

Dwarikesh Sugar Industries saw volume of 2.29 lakh shares, a 5.35-fold rise over two-week average daily volume of 43,000 shares. The stock was up 7.48% at Rs 427.50.

Powered by Capital Market - Live News

Apollo Hospitals drops on reports of stake-sale by a foreign fund
Mar 03,2017

Meanwhile, the S&P BSE Sensex was down 85 points or 0.29% at 28,754.79.

On the BSE, 6.10 lakh shares were traded on the counter so far as against the average daily volumes of 9,335 shares in the past one quarter. The stock had hit a high of Rs 1,288 and a low of Rs 1,246 so far during the day.

The stock had hit a record high of Rs 1,544 on 2 March 2016 and a 52-week low of Rs 1,110.75 on 26 December 2016. It had outperformed the market over the past one month till 2 March 2017, gaining 6.88% compared with the Sensexs 2.17% rise. The scrip had, however, underperformed the market over the past one quarter, advancing 9.65% as against the Sensexs 9.95% rise.

The large-cap company has equity capital of Rs 69.56 crore. Face value per share is Rs 5.

Media reports suggested that Khazanah Berhads subsidiary Integrated (Mauritius) Healthcare Holdings offloaded shares of Apollo Hospitals Enterprise through block deals on the stock exchanges today, 3 March 2017. Integrated (Mauritius) Healthcare Holdings owned 10.85% stake in Apollo Hospitals Enterprise end December 2016.

Apollo Hospitals net profit fell 40.5% to Rs 72.83 crore on 17.9% growth in net sales to Rs 1680.61 crore in Q3 December 2016 over Q3 December 2015.

Apollo Hospitals is one of Asias largest healthcare groups.

Powered by Capital Market - Live News

Lupin gains after receiving final approval from USFDA for generic drug
Mar 03,2017

The announcement was made during market hours today, 3 March 2017.

Meanwhile, the S&P BSE Sensex was down 80.85 points or 0.29% at 28,757.38.

On the BSE, 10,780 shares were traded on the counter so far as against the average daily volumes of 72,224 shares in the past one quarter. The stock had hit a high of Rs 1,472 and a low of Rs 1,456.15 so far during the day.

The stock had hit a 52-week high of Rs 1,874.30 on 14 March 2016 and a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had underperformed the market over the past one month till 2 March 2017, falling 1.52% compared with the Sensexs 2.17% rise. The scrip had also underperformed the market over the past one quarter, falling 1.86% as against the Sensexs 9.95% rise.

The large-cap company has equity capital of Rs 90.31 crore. Face value per share is Rs 2.

Lupin announced that it has received final approval for its Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces from the United States Food & Drug Administration (USFDA) to market a generic version of Braintree Laboratories Suprep Bowel Prep Kit.

Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g is indicated for the cleansing of the colon in preparation for colonoscopy in adults. Suprep Bowel Prep Kit had annual US sales of $207.20 million as per IMS MAT December 2016 data.

Lupins consolidated net profit rose 20.7% to Rs 633.11 crore on 31.5% increase in net sales to Rs 4404.94 crore in Q3 December 2016 over Q3 December 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership position in the anti-TB segment.

Powered by Capital Market - Live News

Balkrishna Industries drops on profit booking
Mar 03,2017

Meanwhile, the S&P BSE Sensex was down 85.51 points, 0.3% to Rs 28,754.28.

On the BSE, 4,647 shares were traded on the counter so far as against the average daily volumes of 12,004 shares in the past one quarter. The stock had hit a high of Rs 1,354.65 and a low of Rs 1,307.85 so far during the day.

The stock had hit a record high of Rs 1,398 on 2 March 2017 and a 52-week low of Rs 572.90 on 2 March 2016. The stock had outperformed the market over the past one month till 2 March 2017, advancing 17.28% compared with the Sensexs 2.17% rise. The scrip had also outperformed the market over the past one quarter advancing 10.16% as against the Sensexs 9.95% rise.

The large-cap company has equity capital of Rs 19.33 crore. Face value per share is Rs 2.

Shares of Balkrishna Industries had rallied 16.49% in the preceding eight trading session to settle at Rs 1,342.05 yesterday, 2 March 2017, from its close of Rs 1,152 on 17 February 2017.

Balkrishna Industries net profit rose 94.2% to Rs 185.69 crore on 25.7% increase in net sales to Rs 864.69 crore in Q3 December 2016 over Q3 December 2015.

Balkrishna Industries is a leading manufacturer in the off-highway tire market. The company has focused on specialist segments such as agricultural, construction and industrial vehicles as well as earthmoving, port and mining, ATV, and gardening applications.

Powered by Capital Market - Live News

Syngene International gains after entering into partnership with Herbalife Nutrition
Mar 03,2017

The announcement was made after market hours yesterday, 2 March 2017.

Meanwhile, the S&P BSE Sensex was down 77.09 points, 0.27% to Rs 28,762.70.

On the BSE, 18,000 shares were traded on the counter so far as against the average daily volumes of 40,750 shares in the past one quarter. The stock had hit a high of Rs 504.40 and a low of Rs 487 so far during the day.

The stock had hit a 52-week high of Rs 663.30 on 9 December 2016 and a 52-week low of Rs 349 on 5 April 2016. The stock had underperformed the market over the past one month till 2 March 2017, declining 10.18% compared with the Sensexs 2.17% rise. The scrip had also underperformed the market over the past one quarter declining 14.86% as against the Sensexs 9.95% rise.

The mid-cap company has equity capital of Rs 200 crore. Face value per share is Rs 10.

Herbalife a global nutrition company, yesterday, 2 March 2017 announced the launch of its first nutrition research and development Lab in India, in partnership with Syngene. The strategic partnership will help Herbalife Nutrition develop and formulate world-class nutrition products for Indian consumers.

The new nutrition research and development facility spans 3,000 square feet, and is located within the Syngene campus at Bangalore. The facility also houses a separate good manufacturing practices (GMP) formulation lab to support product testing, sampling and end-product development.

Ajay Khanna,Vice President and Country Head, Herbalife International India said, practicing good nutrition habits is fast becoming a way of life and it is imperative for the company to ensure that it consistently deliver high quality and affordable products to our consumers.

Dr. Kiran Mazumdar Shaw, Managing Director, Syngene International said, the company is happy to partner with Herbalife in setting up their nutrition research and development Lab.

Syngene Internationals net profit rose 11.54% to Rs 74.40 crore on 17.7% increase in net sales to Rs 323.80 crore in Q3 December 2016 over Q3 December 2015.

Promoted by Biocon, Syngene International is one of Asias largest contract research organizations. The company provides discovery, development and manufacturing services across life-science based industries.

Powered by Capital Market - Live News

New order boosts A2Z Infra Engineering
Mar 03,2017

The announcement was made after market hours yesterday, 2 March 2017.

Meanwhile, the S&P BSE Sensex was down 76.14 points or 0.26% at 28,763.65.

On the BSE, 2.27 lakh shares were traded on the counter so far as against the average daily volumes of 1.93 lakh shares in the past one quarter. The stock had hit a high of Rs 42.45 and a low of Rs 41.30 so far during the day.

The stock had hit a 52-week high of Rs 51.65 on 1 November 2016 and a 52-week low of Rs 19 on 1 April 2016. It had underperformed the market over the past one month till 2 March 2017, sliding 6.79% compared with the Sensexs 2.17% rise. The scrip had also underperformed the market over the past one quarter, advancing 0.63% as against the Sensexs 9.95% rise.

The small-cap company has equity capital of Rs 131.01 crore. Face value per share is Rs 10.

A2Z Infra Engineering said it has been awarded a contract worth $7.06 million from Grid Solar and Energy Efficiency Project, Nepal Electricity Authority for design, supply, delivery, installation, testing and commissioning of substations and lines.

A2Z Infra Engineering reported a net loss of Rs 24.06 crore in Q3 December 2016, higher than net loss of Rs 3.41 crore in Q3 December 2015. Net sales declined 58.1% to Rs 112.38 crore in Q3 December 2016 over Q3 December 2015.

A2Z Infra Engineering (formerly known as A2Z Maintenance & Engineering Services) is a fast growing, fully integrated electrical business group (EBG) in India catering to the needs of domestic and international power sector clients in building distribution and transmission infrastructure.

Powered by Capital Market - Live News

Alembic Pharma gains after launch of drug by partner
Mar 03,2017

The announcement was made during market hours today, 3 March 2016.

Meanwhile, the BSE Sensex was down 70.64 points, or 0.25%, to 28,768.47.

More than usual volumes were witnessed on the counter. On the BSE, 9,588 shares were traded in the counter so far, compared with average daily volumes of 6,237 shares in the past one quarter. The stock had hit a high of Rs 615 and a low of Rs 600 so far during the day.

The stock had hit a 52-week high of Rs 699.50 on 5 October 2016. The stock had hit a 52-week low of Rs 515.55 on 18 April 2016. The stock had outperformed the market over the past one month till 2 March 2017, gaining 7.58% compared with the Sensexs 2.17% rise. The scrip had, however, underperformed the market over the past one quarter, falling 5.61% as against the Sensexs 9.95% rise.

The large-cap company has equity capital of Rs 37.70 crore. Face value per share is Rs 2.

Alembic Pharmaceuticals announced the launch of desvenlafaxine succinate extended-release tablets 50 mg and 100 mg by its partner Breckenridge Pharmaceutical, Inc.

Alembic had received final approval of its abbreviated new drug application (ANDA) which is therapeutically equivalent to the reference listed drug Pristiq of Pfizer Inc. The ANDA was filed as a paragraph IV on the first to file date and will share 180-day exclusivity with other ANDA first filers. Alembic is the manufacturer of the ANDA, which will be marketed exclusively by Breckenridge. The Paragraph IV litigation was settled on terms that are confidential, it added.

Desvenlafaxine is a prescription drug that is indicated for the treatment of major depressive disorder, and is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). Pristiq had an estimated sales of $883 million for twelve months ending December 2016, according to IMS.

Alembic Pharmaceuticals consolidated net profit fell 67.8% to Rs 86.55 crore on 15.9% decline in net sales 769.86 crore in Q3 December 2016 over Q3 December 2015.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, manufactures and markets generic pharmaceutical products all over the world.

Powered by Capital Market - Live News

Hindalco Industries moves higher on qualified institutional placement
Mar 03,2017

The announcement was made after market hours yesterday, 2 March 2017.

Meanwhile, the S&P BSE Sensex was down 86.65 points or 0.3% at 28,753.14.

On the BSE, 8.52 lakh shares were traded on the counter so far as against the average daily volumes of 11.52 lakh shares in the past one quarter. The stock had hit a high of Rs 194.65 and a low of Rs 188 so far during the day.

The stock had hit a 52-week high of Rs 199.90 on 1 February 2017 and a 52-week low of Rs 71.55 on 2 March 2016. It had underperformed the market over the past one month till 2 March 2017, sliding 1.99% compared with the Sensexs 2.17% rise. The scrip had, however, outperformed the market over the past one quarter, advancing 12.26% as against the Sensexs 9.95% rise.

The large-cap company has equity capital of Rs 206.64 crore. Face value per share is Rs 1.

Hindalco Industries qualified institutional placement (QIP) opened yesterday, 2 March 2017. The floor price for the issue is Rs 184.45 per share. The floor price is at a discount of 2.66% to the stocks closing price of Rs 189.50 yesterday, 2 March 2017. There may be a discount of not more than 5% on the floor price for the purpose of evaluating QIP issue price.

Hindalco Industries reported a net profit of Rs 320.56 crore in Q3 December 2016 as against net loss of Rs 32.75 crore in Q3 December 2015. Net sales rose 15.2% to Rs 9226.04 crore in Q3 December 2016 over Q3 December 2015.

Hindalco Industries, metals flagship company of the Aditya Birla Group, is the industry leader in aluminium and copper.

Powered by Capital Market - Live News

Accel Frontline edges higher after board approves entire stake sale in subsidiary
Mar 03,2017

The announcement was made after market hours yesterday, 2 March 2017.

Meanwhile, the BSE Sensex was down 59.57 points or 0.25% at 28,767.16.

On the BSE, 2,025 shares were traded in the counter compared with an average daily volume of 13,995 shares in the past one quarter. The stock had hit high of Rs 69 and low of Rs 68.25 in intraday trade.

The stock had hit a 52-week high of Rs 76 on 24 August 2016. The stock had hit a 52-week low of Rs 45 on 2 March 2016. The stock had outperformed the market over the past one month till 2 March 2017, gaining 11.21% compared with the Sensexs 2.17% rise. The scrip had also outperformed the market over the past one quarter, gaining 17.3% as against the Sensexs 9.95% rise.

The small-cap software company has equity capital of Rs 29.76 crore. Face value per share is Rs 10.

Accel Frontline said that consolidated revenue of this subsidiary was Rs 75.56 crore for the year ended 31 March 2016 (FY 2016). The company said that the buyer for the stake is yet to be identified.

Accel Frontline reported consolidated net loss of Rs 1.99 crore in Q3 December 2016 compared with consolidated net loss of Rs 5.96 crore in Q2 September 2016. The companys net sales rose 17.19% to Rs 156.96 crore in Q3 December 2016 over Q2 September 2016.

Accel Frontline founded in 1991 as Accel Automation, is a leading provider of integrated IT services to small, medium and large enterprises. The company offers engineering and R&D services, outsourced product development, IT infrastructure management, managed services and enterprise applications for the banking, telecom and manufacturing sectors. AFL operates in over 100 locations in India. It has subsidiaries in USA, UAE, Singapore and Japan.

Powered by Capital Market - Live News

RIL surges on promoter shareholding rejig
Mar 03,2017

Meanwhile, the S&P BSE Sensex was down 65.28 points or 0.23% at 28,774.51.

On the BSE, 6.49 lakh shares were traded on the counter so far as against the average daily volumes of 4.03 lakh shares in the past one quarter. The stock had hit a high of Rs 1,287.80 so far during the day, which is a 52-week high for the counter. The stock hit a low of Rs 1,237 so far during the day.

The stock had hit a 52-week low of Rs 925.70 on 23 May 2016. It had outperformed the market over the past one month till 2 March 2017, surging 18.04% compared with the Sensexs 2.17% rise. The scrip had also outperformed the market over the past one quarter, advancing 23.91% as against the Sensexs 9.95% rise.

The large-cap company has equity capital of Rs 3243.98 crore. Face value per share is Rs 10.

The promoter group entities of Reliance Industries (RIL) propose to restructure their shareholding in RIL by inter se transfer of shares among the promoter group entities and have made the necessary disclosures after market hours yesterday, 2 March 2017. The proposed inter se transfers will not result in any change in promoter group shareholding in RIL.

As part of the rejig, the Mukesh Ambani promoter group, which owns a near-majority stake in RIL, plans to shrink the number of firms owning shares in the company.

The promoter group entities acquiring the stake are Devarshi Commercials LLP, Karuna Commercials LLP, Tattvam Enterprises LLP, Srichakra Commercials LLP, Svar Enterprises LLP, Vasuprada Enterprises LLP, Shreeji Comtrade LLP, and Shrikrishna Tradecom LLP.

The above eight promoter group companies of RIL will acquire around 119 crore shares, or 36.7%, from 15 other promoter group companies in an inter se transfer of shares. The transaction will be at Rs 1,100.78 a share, a discount of 10.74% to RILs closing price of Rs 1,233.25 yesterday, 2 March 2017.

The total promoter holding in RIL stood at 45.11% end December 2016. Mukesh Ambani, chairman and managing director of RIL, and his wife and board member Nita Ambani owned 0.11% each in RIL.

RILs consolidated net profit rose 3.6% to Rs 7506 crore on 17.6% growth in net sales to Rs 79408 crore in Q3 December 2016 over Q3 December 2015.

Reliance Industries (RIL) is Indias largest private sector company. RILs activities span hydrocarbon exploration and production, petroleum refining and marketing, petrochemicals, retail and telecommunications.

Powered by Capital Market - Live News

Tata Motors gains on fund raising plans
Mar 03,2017

The announcement was made after market hours yesterday, 2 March 2017.

Meanwhile, the BSE Sensex was down 34.66 points, or 0.14%, to 28,799.26.

On the BSE, 87,698 shares were traded in the counter so far, compared with average daily volumes of 5.59 lakh shares in the past one quarter. The stock had hit a high of Rs 467 and a low of Rs 462.45 so far during the day.

The stock had hit a 52-week high of Rs 598.60 on 7 September 2016. The stock had hit a 52-week low of Rs 314.75 on 2 March 2016. The stock had underperformed the market over the past one month till 2 March 2017, falling 13.15% compared with the Sensexs 2.17% rise. The scrip had also underperformed the market over the past one quarter, gaining 6.47% as against the Sensexs 9.95% rise.

The large-cap auto major has equity capital of Rs 577.47 crore. Face value per share is Rs 2.

Tata Motors announced that the board constituted committee meeting held on 2 March 2017, approved offering for subscription 5,000 rated, listed, unsecured, 7.71% coupon, redeemable, non-convertible debentures of face value of Rs 10 lakh each aggregating up to Rs 500 crore on a private placement basis. NCDs have tenure of 1826 days from the deemed date of allotment. The date of maturity of NCDs is 3 March 2022.

Tata Motors consolidated net profit fell 96.2% to Rs 111.57 crore on 2.2% decline in net sales to Rs 66855.18 crore in Q3 December 2016 over Q3 December 2015.

Tata Motors is a market leader in commercial vehicles in India. The companys British luxury unit Jaguar Land Rover (JLR) sells premium luxury cars.

Powered by Capital Market - Live News

JVL Agro gains as Asia Investment Corp hikes stake
Mar 03,2017

Meanwhile, the S&P BSE Sensex was down 63.98 points or 0.22% at 28,775.81.

On the BSE, 17,000 shares were traded on the counter so far as against the average daily volumes of 79,825 shares in the past one quarter. The stock had hit a high of Rs 20.80 and a low of Rs 20.10 so far during the day.

The stock had hit a 52-week high of Rs 25.45 on 22 June 2016 and a 52-week low of Rs 14 on 22 November 2016. It had underperformed the market over the past one month till 2 March 2017, sliding 6.44% compared with the Sensexs 2.17% rise. The scrip had, however, outperformed the market over the past one quarter, advancing 19.88% as against the Sensexs 9.95% rise.

The small-cap company has equity capital of Rs 16.79 crore. Face value per share is Rs 1.

Asia Investment Corporation (Mauritius) held 2.81% stake in JVL Agro Industries end December 2016.

Shares of JVL Agro Industries were on a declining spree in the recent past. The stock had fallen 6.44% in the preceding four trading sessions to settle at Rs 19.60 yesterday, 2 March 2017, from its close of Rs 20.95 on 23 February 2017.

JVL Agro Industries net profit fell 21.5% to Rs 10.78 crore on 8.2% decline in net sales to Rs 1042 crore in Q3 December 2016 over Q3 December 2015.

JVL Agro Industries is engaged in the operations related to production of vanaspati, refine and mustard oil, and trading of goods.

Powered by Capital Market - Live News